ADAM10

Across TCGA pan-cancer cohorts, ADAM10 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAM10 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ADAM10 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAM10 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, CESC, and LIHC are the cancer types where ADAM10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.634	.019	28	view →
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	24	view →
LIHC	OS	Median	All	0.094	0.783	<.001	21	view →
OV	DFS	Median	All	0.165	0.541	.004	18	view →
BLCA	OS	Median	IV	0.509	0.284	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAM10–UCEC (DFS)

Open the UCEC breakdown →